Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients

With the introduction of novel therapeutic agents, survival in Multiple Myeloma (MM) has increased in recent years. However, drug-resistant clones inevitably arise and lead to disease progression and death. The current International Myeloma Working Group response criteria are broad and make it diffi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tierney, Ciara, Bazou, Despina, Majumder, Muntasir M., Anttila, Pekka, Silvennoinen, Raija, Heckman, Caroline A., Dowling, Paul, O’Gorman, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213739/
https://www.ncbi.nlm.nih.gov/pubmed/34145309
http://dx.doi.org/10.1038/s41598-021-90149-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213739/
https://www.ncbi.nlm.nih.gov/pubmed/34145309
http://dx.doi.org/10.1038/s41598-021-90149-y

Ejemplares similares